265 related articles for article (PubMed ID: 28223185)
1. Nanomedicine as a potent strategy in melanoma tumor microenvironment.
Pautu V; Leonetti D; Lepeltier E; Clere N; Passirani C
Pharmacol Res; 2017 Dec; 126():31-53. PubMed ID: 28223185
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticle-mediated drug delivery for treating melanoma.
Mundra V; Li W; Mahato RI
Nanomedicine (Lond); 2015; 10(16):2613-33. PubMed ID: 26244818
[TBL] [Abstract][Full Text] [Related]
3. Nano-drug delivery system targeting tumor microenvironment: A prospective strategy for melanoma treatment.
Xu M; Li S
Cancer Lett; 2023 Oct; 574():216397. PubMed ID: 37730105
[TBL] [Abstract][Full Text] [Related]
4. Physical oncology: New targets for nanomedicine.
Nicolas-Boluda A; Silva AKA; Fournel S; Gazeau F
Biomaterials; 2018 Jan; 150():87-99. PubMed ID: 29035739
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Polymeric Nanosystems for Treating Cutaneous Melanoma and Its Metastasis.
Chou YP; Lin YK; Chen CH; Fang JY
Curr Pharm Des; 2017; 23(35):5301-5314. PubMed ID: 28699537
[TBL] [Abstract][Full Text] [Related]
6. Nanotherapy Targeting the Tumor Microenvironment.
Gong BS; Wang R; Xu HX; Miao MY; Yao ZZ
Curr Cancer Drug Targets; 2019; 19(7):525-533. PubMed ID: 30569855
[TBL] [Abstract][Full Text] [Related]
7. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
8. Optimization of the tumor microenvironment and nanomedicine properties simultaneously to improve tumor therapy.
Zhang B; Shi W; Jiang T; Wang L; Mei H; Lu H; Hu Y; Pang Z
Oncotarget; 2016 Sep; 7(38):62607-62618. PubMed ID: 27566585
[TBL] [Abstract][Full Text] [Related]
9. Recent developments in nanomedicine for melanoma treatment.
Tang JQ; Hou XY; Yang CS; Li YX; Xin Y; Guo WW; Wei ZP; Liu YQ; Jiang G
Int J Cancer; 2017 Aug; 141(4):646-653. PubMed ID: 28340496
[TBL] [Abstract][Full Text] [Related]
10. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor in the neighborhood reverses resistance to BRAF inhibitor in melanoma.
Nickoloff BJ; Vande Woude G
Pigment Cell Melanoma Res; 2012 Nov; 25(6):758-61. PubMed ID: 22974232
[No Abstract] [Full Text] [Related]
12. Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles.
Niu Y; Zhu J; Li Y; Shi H; Gong Y; Li R; Huo Q; Ma T; Liu Y
J Control Release; 2018 May; 277():35-47. PubMed ID: 29545106
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
[TBL] [Abstract][Full Text] [Related]
14. Smart nanoparticles improve therapy for drug-resistant tumors by overcoming pathophysiological barriers.
Liu JP; Wang TT; Wang DG; Dong AJ; Li YP; Yu HJ
Acta Pharmacol Sin; 2017 Jan; 38(1):1-8. PubMed ID: 27569390
[TBL] [Abstract][Full Text] [Related]
15. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment.
David A
Adv Drug Deliv Rev; 2017 Sep; 119():120-142. PubMed ID: 28506743
[TBL] [Abstract][Full Text] [Related]
16. New strategies in melanoma therapy: can nanoparticles overcome chemoresistance?
Badea I
Nanomedicine (Lond); 2017 Jul; 12(14):1623-1626. PubMed ID: 28635551
[No Abstract] [Full Text] [Related]
17. Systemic treatment for BRAF-mutant melanoma: where do we go next?
Menzies AM; Long GV
Lancet Oncol; 2014 Aug; 15(9):e371-81. PubMed ID: 25079100
[TBL] [Abstract][Full Text] [Related]
18. Exploring the tumor microenvironment with nanoparticles.
Miao L; Huang L
Cancer Treat Res; 2015; 166():193-226. PubMed ID: 25895870
[TBL] [Abstract][Full Text] [Related]
19. Radiation effects on the tumor microenvironment: Implications for nanomedicine delivery.
Stapleton S; Jaffray D; Milosevic M
Adv Drug Deliv Rev; 2017 Jan; 109():119-130. PubMed ID: 27262923
[TBL] [Abstract][Full Text] [Related]
20. Tumor-selective catalytic nanomedicine by nanocatalyst delivery.
Huo M; Wang L; Chen Y; Shi J
Nat Commun; 2017 Aug; 8(1):357. PubMed ID: 28842577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
